Great Novel Therapeutics Biotech & Medicals (7427) fair value: what the stock is really worth
As of Nov 17, 2026: fair value (intrinsic value) of Great Novel Therapeutics Biotech & Medicals stock TWD 31.17, price TWD 54.50, that is 42.8% below the price, quality 23 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Great Novel Therapeutics Biotech & Medicals
7427 · TWOFar too expensive (fair value 43% below the price) and weak company.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
12‑month range 30.00 TWD – 78.00 TWD · fair‑value band 23.38 TWD – 38.97 TWD · the 54.50 TWD price screens above the 31.17 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Great Novel Therapeutics Biotech & Medicals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers in Taiwan.
Show moreShow less
The company develops GNTbm-38, an epigenetic immune-activating drug independently developed by GNTbm for cancer immunotherapy; and GNTbm-TKI, a potent inhibitor of TYRO-3, AXL, c-MER, BTK, ROS1, NTRK2, MET, and VEGFR2 for immune regulation, tumor growth inhibition, metastasis and invasion suppresion, and anti-angiogenesis activity.
It is also developing Kepida to treat HR+/her-2 advanced breast cancer and Peripheral T-cell lymphoma. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was incorporated in 2013 and is based in Taipei, Taiwan.
Stock analysis
Great Novel Therapeutics Biotech & Medicals (7427) currently trades at 54.50 TWD, while our estimate is 31.17 TWD, 43% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 23.38 TWD (bear) to 38.97 TWD (bull), the price of 54.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 23/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Great Novel Therapeutics Biotech & Medicals reported revenue of 1.2M TWD in FY2025 versus 630K TWD in FY2021, a compound +17.6%/yr. Reported net income was −97.5M TWD in FY2025.
Key figures
Market cap 2.9B TWD (≈ $87.3M) Micro · EPS (TTM) −2.45 TWD · Return on equity −17.0% · Return on assets (EBIT) −15.5% (5-year average) · Operating margin −1,092% · Revenue growth (YoY) +803% · Free cash flow −91.1M TWD · Net cash 145M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 82% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −43%, 7427 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Great Novel Therapeutics Biotech & Medicals with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Price/FCF by industry
- Debt-to-equity by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Taiwanese Stocks
- Valuation of the Taiwan market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 7427 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 7427 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 7427 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 7427 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 7427 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 7427 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 7427 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 7427 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 7427 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 7427 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Great Novel Therapeutics Biotech & Medicals (7427) overvalued or undervalued?
What is the fair value of 7427?
What is the quality score of 7427?
What is the price target for Great Novel Therapeutics Biotech & Medicals (7427)?
What is the Great Novel Therapeutics Biotech & Medicals stock forecast for 2026?
What is the intrinsic value of Great Novel Therapeutics Biotech & Medicals (7427)?
Is Great Novel Therapeutics Biotech & Medicals stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 7427?
How much is Great Novel Therapeutics Biotech & Medicals worth?
What do the bullish and bearish scenarios say about 7427?
How solid is the balance sheet of Great Novel Therapeutics Biotech & Medicals (7427)?
How far is 7427 from its 52-week high?
Which stocks are comparable to Great Novel Therapeutics Biotech & Medicals?
Is Great Novel Therapeutics Biotech & Medicals stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Great Novel Therapeutics Biotech & Medicals (7427)?
What should I pay attention to with Great Novel Therapeutics Biotech & Medicals right now?
Key figures of Great Novel Therapeutics Biotech & Medicals
How large is the market capitalisation of Great Novel Therapeutics Biotech & Medicals (7427)?
What are the earnings per share of Great Novel Therapeutics Biotech & Medicals (7427)?
What is the return on equity of Great Novel Therapeutics Biotech & Medicals (7427)?
What is the EBIT return on assets of Great Novel Therapeutics Biotech & Medicals (7427)?
What is the operating margin of Great Novel Therapeutics Biotech & Medicals (7427)?
How fast is revenue growing at Great Novel Therapeutics Biotech & Medicals (7427)?
How much free cash flow does Great Novel Therapeutics Biotech & Medicals (7427) generate?
How much net cash does Great Novel Therapeutics Biotech & Medicals (7427) hold?
Watch Great Novel Therapeutics Biotech & Medicals in the live analysis
One click puts Great Novel Therapeutics Biotech & Medicals on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.